Antidiabetic Bis-Maltolato-OxoVanadium(IV): Conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B
Thomas Scior1, Hans-Georg Mack2, José Antonio Guevara García3, Wolfhard Koch41Departamento de Farmacia. Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Colonia San Manuel, Puebla, Mexico; 2Institut f...
Main Authors: | Thomas Scior, Hans-Georg Mack, José Antonio Guevara García, Wolfhard Koch |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2008-11-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/antidiabetic-bis-maltolato-oxovanadiumiv-conversion-of-inactive-trans--a2591 |
Similar Items
-
Changes in Iron Metabolism and Oxidative Status in STZ-Induced Diabetic Rats Treated with Bis(maltolato) Oxovanadium (IV) as an Antidiabetic Agent
by: Cristina Sánchez-González, et al.
Published: (2014-01-01) -
Bis(maltolato)oxovanadium(IV) Induces Angiogenesis via Phosphorylation of VEGFR2
by: Laura Parma, et al.
Published: (2020-06-01) -
Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B
by: Thomas Scior, et al.
Published: (2010-09-01) -
An investigation into the antidiabetic and catalytic properties of oxovanadium(IV) complexes
by: Walmsley, Ryan Steven
Published: (2012) -
Vanadium Compounds as PTP Inhibitors
by: Elsa Irving, et al.
Published: (2017-12-01)